Share Price and Basic Stock Data
Last Updated: November 28, 2025, 7:30 am
| PEG Ratio | 0.67 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Alpa Laboratories Ltd operates in the pharmaceuticals industry, with a current market capitalization of ₹166 Cr and a share price of ₹79.00. The company has demonstrated fluctuating revenue trends over the past several quarters. For instance, sales reported for June 2022 stood at ₹22 Cr, which peaked at ₹29 Cr in March 2023 before declining to ₹24 Cr by March 2024. The latest figures for June 2025 show sales at ₹19 Cr, indicating a decline from the prior quarter’s ₹39 Cr. Over the past fiscal year, Alpa’s total revenue was reported at ₹109 Cr, consistent with the trailing twelve months (TTM) figure. Despite the recent volatility, the company’s sales have shown a growth trajectory from ₹97 Cr in FY 2021 to ₹112 Cr in FY 2022, before declining to ₹93 Cr in FY 2023. This inconsistency reflects potential challenges in maintaining market share amidst competitive pressures in the pharmaceutical sector.
Profitability and Efficiency Metrics
Alpa Laboratories has reported a modest operating profit margin (OPM) of 2% as of the latest figures. Historical data reveals fluctuations in profitability, with OPM reaching a high of 32% in March 2023 before declining. The net profit for FY 2025 was recorded at ₹20 Cr, which translates to a net profit margin of 17.34%, a notable improvement over the previous year’s margin of 15.42%. The company’s return on equity (ROE) is reported at 11.5%, while return on capital employed (ROCE) stands at 15.0%. These figures suggest that while profitability has not been consistently high, Alpa has managed to maintain a reasonable return on investments. However, the company’s cash conversion cycle (CCC) remains extended at 150 days, indicating potential inefficiencies in working capital management. This extended cycle could impact liquidity, posing challenges in meeting operational expenses without external financing.
Balance Sheet Strength and Financial Ratios
Alpa Laboratories has a robust balance sheet, evidenced by zero borrowings and total reserves increasing to ₹161 Cr as of March 2025. The company has maintained a current ratio of 4.10, indicating strong liquidity and the ability to cover short-term liabilities. The interest coverage ratio (ICR) is exceptionally high at 121.23x, reflecting an absence of debt and an ability to meet interest obligations comfortably. The price-to-book value (P/BV) ratio stands at 1.28x, suggesting that the stock is trading at a premium relative to its book value, which is ₹81.48 per share. This indicates investor confidence in the company’s future growth prospects. However, the operating profit has shown a downward trend, with the latest operating profit reported at ₹5 Cr for FY 2025, which could raise concerns regarding operational efficiency in the long run.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Alpa Laboratories reveals a stable ownership structure, with promoters holding 57.29% of the company. This level of promoter ownership suggests a strong commitment to the company’s growth. The public holds 42.36% of the shares, and foreign institutional investors (FIIs) have gradually increased their stake from 0% to 0.95% by December 2023, indicating growing interest from external investors. The number of shareholders has slightly decreased over recent quarters, from 19,094 in December 2022 to 18,542 as of September 2025. This decline may reflect investor concerns regarding the company’s performance and market position, potentially impacting liquidity. Nevertheless, the consistent promoter shareholding can be seen as a positive indicator of stability and long-term commitment, which may help in retaining investor confidence.
Outlook, Risks, and Final Insight
Looking ahead, Alpa Laboratories faces both opportunities and challenges. The company’s strong balance sheet, with no debt and significant reserves, positions it well for potential investments in growth initiatives. However, the volatility in sales and profitability metrics raises concerns about the sustainability of its current performance. Risks include the competitive landscape of the pharmaceutical industry, which may pressure margins and market share. Additionally, the extended cash conversion cycle could hinder operational flexibility. If Alpa can improve operational efficiencies and stabilize revenue streams, it may enhance profitability and shareholder value. Conversely, continued sales declines without strategic adjustments could challenge the company’s long-term viability. The path forward will require a careful balance of expansion efforts and operational management to mitigate risks while capitalizing on growth opportunities.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Alpa Laboratories Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 149 Cr. | 118 | 247/84.3 | 32.9 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,425 Cr. | 406 | 479/192 | 91.6 | 24.3 | 0.16 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 33.0 Cr. | 44.5 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 42.5 Cr. | 29.0 | 29.3/17.0 | 101 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,561.99 Cr | 1,174.44 | 52.22 | 202.44 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 22 | 14 | 27 | 29 | 25 | 32 | 27 | 24 | 21 | 25 | 26 | 39 | 19 |
| Expenses | 21 | 19 | 25 | 20 | 27 | 29 | 25 | 20 | 21 | 22 | 25 | 39 | 19 |
| Operating Profit | 1 | -6 | 3 | 9 | -1 | 3 | 2 | 4 | 1 | 3 | 1 | -0 | 0 |
| OPM % | 6% | -42% | 10% | 32% | -5% | 10% | 9% | 15% | 3% | 13% | 3% | -1% | 2% |
| Other Income | 2 | 6 | 3 | -1 | 4 | 3 | 4 | 4 | 5 | 7 | 9 | 3 | 12 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 3 | 0 | 5 | 8 | 3 | 6 | 5 | 7 | 5 | 10 | 9 | 2 | 12 |
| Tax % | -0% | -0% | -0% | 42% | -0% | -0% | 15% | 47% | -0% | 20% | -0% | 187% | -0% |
| Net Profit | 3 | 0 | 5 | 5 | 3 | 6 | 5 | 4 | 5 | 8 | 9 | -2 | 12 |
| EPS in Rs | 1.26 | 0.10 | 2.44 | 2.20 | 1.44 | 2.73 | 2.15 | 1.69 | 2.43 | 3.63 | 4.23 | -0.93 | 5.60 |
Last Updated: August 20, 2025, 1:55 pm
Below is a detailed analysis of the quarterly data for Alpa Laboratories Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 19.00 Cr.. The value appears to be declining and may need further review. It has decreased from 39.00 Cr. (Mar 2025) to 19.00 Cr., marking a decrease of 20.00 Cr..
- For Expenses, as of Jun 2025, the value is 19.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 39.00 Cr. (Mar 2025) to 19.00 Cr., marking a decrease of 20.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For OPM %, as of Jun 2025, the value is 2.00%. The value appears strong and on an upward trend. It has increased from -1.00% (Mar 2025) to 2.00%, marking an increase of 3.00%.
- For Other Income, as of Jun 2025, the value is 12.00 Cr.. The value appears strong and on an upward trend. It has increased from 3.00 Cr. (Mar 2025) to 12.00 Cr., marking an increase of 9.00 Cr..
- For Interest, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Depreciation, as of Jun 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 1.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 12.00 Cr.. The value appears strong and on an upward trend. It has increased from 2.00 Cr. (Mar 2025) to 12.00 Cr., marking an increase of 10.00 Cr..
- For Tax %, as of Jun 2025, the value is 0.00%. The value appears to be improving (decreasing) as expected. It has decreased from 187.00% (Mar 2025) to 0.00%, marking a decrease of 187.00%.
- For Net Profit, as of Jun 2025, the value is 12.00 Cr.. The value appears strong and on an upward trend. It has increased from -2.00 Cr. (Mar 2025) to 12.00 Cr., marking an increase of 14.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 5.60. The value appears strong and on an upward trend. It has increased from -0.93 (Mar 2025) to 5.60, marking an increase of 6.53.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 5:44 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 56 | 57 | 53 | 63 | 62 | 77 | 85 | 97 | 112 | 93 | 109 | 110 | 109 |
| Expenses | 51 | 54 | 47 | 56 | 57 | 76 | 79 | 90 | 101 | 85 | 100 | 105 | 105 |
| Operating Profit | 6 | 3 | 7 | 7 | 4 | 1 | 6 | 8 | 11 | 8 | 9 | 5 | 4 |
| OPM % | 10% | 6% | 13% | 11% | 7% | 2% | 7% | 8% | 10% | 9% | 8% | 5% | 4% |
| Other Income | 1 | 2 | 6 | 4 | 5 | 5 | 0 | 4 | 11 | 9 | 14 | 23 | 31 |
| Interest | 2 | 2 | 1 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 9 | 6 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 2 | 2 | 2 |
| Profit before tax | -5 | -3 | 11 | 9 | 7 | 5 | 5 | 11 | 20 | 16 | 21 | 26 | 33 |
| Tax % | 4% | -48% | 27% | 34% | 27% | 36% | 20% | 33% | 28% | 21% | 19% | 24% | |
| Net Profit | -5 | -1 | 8 | 6 | 5 | 3 | 4 | 7 | 14 | 13 | 17 | 20 | 26 |
| EPS in Rs | -2.45 | -0.67 | 3.68 | 2.85 | 2.27 | 1.40 | 1.94 | 3.45 | 6.72 | 6.00 | 7.98 | 9.35 | 12.53 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 80.00% | 900.00% | -25.00% | -16.67% | -40.00% | 33.33% | 75.00% | 100.00% | -7.14% | 30.77% | 17.65% |
| Change in YoY Net Profit Growth (%) | 0.00% | 820.00% | -925.00% | 8.33% | -23.33% | 73.33% | 41.67% | 25.00% | -107.14% | 37.91% | -13.12% |
Alpa Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 6% |
| 3 Years: | 0% |
| TTM: | 4% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 55% |
| 5 Years: | 30% |
| 3 Years: | 36% |
| TTM: | 39% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 19% |
| 5 Years: | 27% |
| 3 Years: | 15% |
| 1 Year: | -8% |
| Return on Equity | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 9% |
| 3 Years: | 11% |
| Last Year: | 11% |
Last Updated: September 4, 2025, 11:00 pm
Balance Sheet
Last Updated: June 16, 2025, 12:30 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 |
| Reserves | 67 | 66 | 73 | 77 | 82 | 85 | 89 | 96 | 111 | 124 | 141 | 161 |
| Borrowings | 23 | 29 | 24 | 11 | 6 | 2 | 0 | 0 | 6 | 3 | 5 | 0 |
| Other Liabilities | 15 | 13 | 27 | 20 | 17 | 21 | 21 | 33 | 28 | 30 | 25 | 51 |
| Total Liabilities | 127 | 128 | 145 | 129 | 127 | 129 | 131 | 150 | 165 | 178 | 192 | 233 |
| Fixed Assets | 73 | 5 | 5 | 5 | 6 | 6 | 6 | 7 | 9 | 7 | 11 | 21 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 0 |
| Investments | 0 | 10 | 22 | 23 | 41 | 59 | 68 | 62 | 86 | 90 | 109 | 129 |
| Other Assets | 54 | 113 | 118 | 100 | 79 | 64 | 56 | 80 | 70 | 81 | 72 | 83 |
| Total Assets | 127 | 128 | 145 | 129 | 127 | 129 | 131 | 150 | 165 | 178 | 192 | 233 |
Below is a detailed analysis of the balance sheet data for Alpa Laboratories Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 21.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 21.00 Cr..
- For Reserves, as of Mar 2025, the value is 161.00 Cr.. The value appears strong and on an upward trend. It has increased from 141.00 Cr. (Mar 2024) to 161.00 Cr., marking an increase of 20.00 Cr..
- For Borrowings, as of Mar 2025, the value is 0.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 5.00 Cr. (Mar 2024) to 0.00 Cr., marking a decrease of 5.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 51.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 25.00 Cr. (Mar 2024) to 51.00 Cr., marking an increase of 26.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 233.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 192.00 Cr. (Mar 2024) to 233.00 Cr., marking an increase of 41.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 21.00 Cr.. The value appears strong and on an upward trend. It has increased from 11.00 Cr. (Mar 2024) to 21.00 Cr., marking an increase of 10.00 Cr..
- For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Investments, as of Mar 2025, the value is 129.00 Cr.. The value appears strong and on an upward trend. It has increased from 109.00 Cr. (Mar 2024) to 129.00 Cr., marking an increase of 20.00 Cr..
- For Other Assets, as of Mar 2025, the value is 83.00 Cr.. The value appears strong and on an upward trend. It has increased from 72.00 Cr. (Mar 2024) to 83.00 Cr., marking an increase of 11.00 Cr..
- For Total Assets, as of Mar 2025, the value is 233.00 Cr.. The value appears strong and on an upward trend. It has increased from 192.00 Cr. (Mar 2024) to 233.00 Cr., marking an increase of 41.00 Cr..
Notably, the Reserves (161.00 Cr.) exceed the Borrowings (0.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -17.00 | -26.00 | -17.00 | -4.00 | -2.00 | -1.00 | 6.00 | 8.00 | 5.00 | 5.00 | 4.00 | 5.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 130 | 156 | 234 | 169 | 151 | 141 | 105 | 133 | 124 | 186 | 138 | 155 |
| Inventory Days | 148 | 76 | 196 | 131 | 140 | 105 | 90 | 102 | 81 | 84 | 73 | 92 |
| Days Payable | 121 | 91 | 244 | 140 | 130 | 99 | 98 | 152 | 78 | 100 | 63 | 97 |
| Cash Conversion Cycle | 157 | 141 | 187 | 160 | 161 | 148 | 97 | 83 | 127 | 170 | 149 | 150 |
| Working Capital Days | 65 | -4 | 224 | 197 | 204 | 189 | 121 | 137 | 124 | 150 | 132 | 108 |
| ROCE % | -3% | 0% | 10% | 11% | 7% | 4% | 7% | 7% | 9% | 11% | 14% | 15% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 9.34 | 8.01 | 5.88 | 6.70 | 3.44 |
| Diluted EPS (Rs.) | 9.34 | 8.01 | 5.88 | 6.70 | 3.44 |
| Cash EPS (Rs.) | 10.32 | 8.90 | 6.61 | 7.48 | 4.03 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 81.48 | 72.20 | 63.96 | 57.85 | 51.16 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 81.48 | 72.20 | 63.96 | 57.85 | 51.16 |
| Revenue From Operations / Share (Rs.) | 53.45 | 51.68 | 44.18 | 53.36 | 46.36 |
| PBDIT / Share (Rs.) | 13.36 | 10.93 | 8.29 | 10.19 | 5.75 |
| PBIT / Share (Rs.) | 12.31 | 10.00 | 7.66 | 9.40 | 5.16 |
| PBT / Share (Rs.) | 12.20 | 9.83 | 7.55 | 9.30 | 5.13 |
| Net Profit / Share (Rs.) | 9.27 | 7.97 | 5.98 | 6.70 | 3.44 |
| NP After MI And SOA / Share (Rs.) | 9.27 | 7.97 | 5.98 | 6.70 | 3.44 |
| PBDIT Margin (%) | 24.98 | 21.14 | 18.76 | 19.09 | 12.39 |
| PBIT Margin (%) | 23.03 | 19.35 | 17.33 | 17.61 | 11.13 |
| PBT Margin (%) | 22.82 | 19.01 | 17.09 | 17.42 | 11.05 |
| Net Profit Margin (%) | 17.34 | 15.42 | 13.53 | 12.55 | 7.42 |
| NP After MI And SOA Margin (%) | 17.34 | 15.42 | 13.53 | 12.55 | 7.42 |
| Return on Networth / Equity (%) | 11.37 | 11.04 | 9.34 | 11.57 | 6.73 |
| Return on Capital Employeed (%) | 14.72 | 13.63 | 11.90 | 15.97 | 10.07 |
| Return On Assets (%) | 8.76 | 9.19 | 7.52 | 9.07 | 5.16 |
| Long Term Debt / Equity (X) | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 |
| Total Debt / Equity (X) | 0.00 | 0.03 | 0.01 | 0.04 | 0.00 |
| Asset Turnover Ratio (%) | 0.55 | 0.62 | 0.57 | 0.73 | 0.71 |
| Current Ratio (X) | 4.10 | 5.74 | 4.67 | 4.43 | 3.73 |
| Quick Ratio (X) | 3.72 | 5.25 | 4.28 | 3.93 | 3.22 |
| Inventory Turnover Ratio (X) | 4.52 | 4.78 | 3.73 | 3.96 | 3.73 |
| Interest Coverage Ratio (X) | 121.23 | 64.02 | 78.01 | 97.84 | 155.24 |
| Interest Coverage Ratio (Post Tax) (X) | 85.14 | 47.71 | 57.27 | 65.32 | 94.03 |
| Enterprise Value (Cr.) | 216.89 | 179.04 | 106.65 | 149.57 | 65.56 |
| EV / Net Operating Revenue (X) | 1.93 | 1.65 | 1.15 | 1.33 | 0.67 |
| EV / EBITDA (X) | 7.72 | 7.79 | 6.11 | 6.98 | 5.42 |
| MarketCap / Net Operating Revenue (X) | 1.95 | 1.61 | 1.22 | 1.30 | 0.77 |
| Price / BV (X) | 1.28 | 1.16 | 0.84 | 1.20 | 0.70 |
| Price / Net Operating Revenue (X) | 1.95 | 1.61 | 1.22 | 1.30 | 0.77 |
| EarningsYield | 0.08 | 0.09 | 0.11 | 0.09 | 0.09 |
After reviewing the key financial ratios for Alpa Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 9.34. This value is within the healthy range. It has increased from 8.01 (Mar 24) to 9.34, marking an increase of 1.33.
- For Diluted EPS (Rs.), as of Mar 25, the value is 9.34. This value is within the healthy range. It has increased from 8.01 (Mar 24) to 9.34, marking an increase of 1.33.
- For Cash EPS (Rs.), as of Mar 25, the value is 10.32. This value is within the healthy range. It has increased from 8.90 (Mar 24) to 10.32, marking an increase of 1.42.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 81.48. It has increased from 72.20 (Mar 24) to 81.48, marking an increase of 9.28.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 81.48. It has increased from 72.20 (Mar 24) to 81.48, marking an increase of 9.28.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 53.45. It has increased from 51.68 (Mar 24) to 53.45, marking an increase of 1.77.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 13.36. This value is within the healthy range. It has increased from 10.93 (Mar 24) to 13.36, marking an increase of 2.43.
- For PBIT / Share (Rs.), as of Mar 25, the value is 12.31. This value is within the healthy range. It has increased from 10.00 (Mar 24) to 12.31, marking an increase of 2.31.
- For PBT / Share (Rs.), as of Mar 25, the value is 12.20. This value is within the healthy range. It has increased from 9.83 (Mar 24) to 12.20, marking an increase of 2.37.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 9.27. This value is within the healthy range. It has increased from 7.97 (Mar 24) to 9.27, marking an increase of 1.30.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 9.27. This value is within the healthy range. It has increased from 7.97 (Mar 24) to 9.27, marking an increase of 1.30.
- For PBDIT Margin (%), as of Mar 25, the value is 24.98. This value is within the healthy range. It has increased from 21.14 (Mar 24) to 24.98, marking an increase of 3.84.
- For PBIT Margin (%), as of Mar 25, the value is 23.03. This value exceeds the healthy maximum of 20. It has increased from 19.35 (Mar 24) to 23.03, marking an increase of 3.68.
- For PBT Margin (%), as of Mar 25, the value is 22.82. This value is within the healthy range. It has increased from 19.01 (Mar 24) to 22.82, marking an increase of 3.81.
- For Net Profit Margin (%), as of Mar 25, the value is 17.34. This value exceeds the healthy maximum of 10. It has increased from 15.42 (Mar 24) to 17.34, marking an increase of 1.92.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 17.34. This value is within the healthy range. It has increased from 15.42 (Mar 24) to 17.34, marking an increase of 1.92.
- For Return on Networth / Equity (%), as of Mar 25, the value is 11.37. This value is below the healthy minimum of 15. It has increased from 11.04 (Mar 24) to 11.37, marking an increase of 0.33.
- For Return on Capital Employeed (%), as of Mar 25, the value is 14.72. This value is within the healthy range. It has increased from 13.63 (Mar 24) to 14.72, marking an increase of 1.09.
- For Return On Assets (%), as of Mar 25, the value is 8.76. This value is within the healthy range. It has decreased from 9.19 (Mar 24) to 8.76, marking a decrease of 0.43.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. It has decreased from 0.03 (Mar 24) to 0.00, marking a decrease of 0.03.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.55. It has decreased from 0.62 (Mar 24) to 0.55, marking a decrease of 0.07.
- For Current Ratio (X), as of Mar 25, the value is 4.10. This value exceeds the healthy maximum of 3. It has decreased from 5.74 (Mar 24) to 4.10, marking a decrease of 1.64.
- For Quick Ratio (X), as of Mar 25, the value is 3.72. This value exceeds the healthy maximum of 2. It has decreased from 5.25 (Mar 24) to 3.72, marking a decrease of 1.53.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.52. This value is within the healthy range. It has decreased from 4.78 (Mar 24) to 4.52, marking a decrease of 0.26.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 121.23. This value is within the healthy range. It has increased from 64.02 (Mar 24) to 121.23, marking an increase of 57.21.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 85.14. This value is within the healthy range. It has increased from 47.71 (Mar 24) to 85.14, marking an increase of 37.43.
- For Enterprise Value (Cr.), as of Mar 25, the value is 216.89. It has increased from 179.04 (Mar 24) to 216.89, marking an increase of 37.85.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.93. This value is within the healthy range. It has increased from 1.65 (Mar 24) to 1.93, marking an increase of 0.28.
- For EV / EBITDA (X), as of Mar 25, the value is 7.72. This value is within the healthy range. It has decreased from 7.79 (Mar 24) to 7.72, marking a decrease of 0.07.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.95. This value is within the healthy range. It has increased from 1.61 (Mar 24) to 1.95, marking an increase of 0.34.
- For Price / BV (X), as of Mar 25, the value is 1.28. This value is within the healthy range. It has increased from 1.16 (Mar 24) to 1.28, marking an increase of 0.12.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.95. This value is within the healthy range. It has increased from 1.61 (Mar 24) to 1.95, marking an increase of 0.34.
- For EarningsYield, as of Mar 25, the value is 0.08. This value is below the healthy minimum of 5. It has decreased from 0.09 (Mar 24) to 0.08, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Alpa Laboratories Ltd:
- Net Profit Margin: 17.34%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 14.72% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 11.37% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 85.14
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 3.72
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 8.93 (Industry average Stock P/E: 52.22)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 17.34%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 33/2, Pigdamber, A.B.Road, Rau, Indore Madhya Pradesh 453446 | is@alpalabs.in http://www.alpalabs.in |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Mahendra Singh Chawla | Chairman |
| Mr. Paresh Chawla | Managing Director |
| Mrs. Jyoti Jain | Independent Director |
| Mr. Pravin Shah | Director |
| Mr. Vitthal Kothana | Director |
| Mr. Sanket Baheti | Independent Director |
| Mr. Shitul Shah | Director |
| Mr. Sunil Kumar Valecha | Independent Director |
| Mrs. Pratibha Lunawat | Independent Director |
FAQ
What is the intrinsic value of Alpa Laboratories Ltd?
Alpa Laboratories Ltd's intrinsic value (as of 03 December 2025) is 77.10 which is 3.75% lower the current market price of 80.10, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 168 Cr. market cap, FY2025-2026 high/low of 137/75.6, reserves of ₹161 Cr, and liabilities of 233 Cr.
What is the Market Cap of Alpa Laboratories Ltd?
The Market Cap of Alpa Laboratories Ltd is 168 Cr..
What is the current Stock Price of Alpa Laboratories Ltd as on 03 December 2025?
The current stock price of Alpa Laboratories Ltd as on 03 December 2025 is 80.1.
What is the High / Low of Alpa Laboratories Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Alpa Laboratories Ltd stocks is 137/75.6.
What is the Stock P/E of Alpa Laboratories Ltd?
The Stock P/E of Alpa Laboratories Ltd is 8.93.
What is the Book Value of Alpa Laboratories Ltd?
The Book Value of Alpa Laboratories Ltd is 92.0.
What is the Dividend Yield of Alpa Laboratories Ltd?
The Dividend Yield of Alpa Laboratories Ltd is 0.00 %.
What is the ROCE of Alpa Laboratories Ltd?
The ROCE of Alpa Laboratories Ltd is 15.0 %.
What is the ROE of Alpa Laboratories Ltd?
The ROE of Alpa Laboratories Ltd is 11.5 %.
What is the Face Value of Alpa Laboratories Ltd?
The Face Value of Alpa Laboratories Ltd is 10.0.